Vera Therapeutics, Inc VERA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-05-14 |
| Shares Out. | 71,780,000 |
| Website | veratx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 339 |
| Net Income | -$122.0M |
| Free Cash Flow | -$293.8M |
| Total Assets | $621.7M |
| Total Liabilities | $122.0M |
| Equity | $499.7M |
About Vera Therapeutics, Inc
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Vera Therapeutics, Inc is a publicly traded company under the ticker symbol VERA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-07-01)